European Journal of Medicinal Chemistry (2021)
Update date:2022-08-03
Topics: In vitro Testing Clinical Trials In Vivo Testing Combination Therapies Regulatory Approval
Tabti, Redouane
Lamoureux, Fran?ois
Charrier, Céline
Ory, Benjamin
Heymann, Dominique
Bentouhami, Embarek
Désaubry, Laurent
Current therapeutic approaches to osteoporosis display some potential adverse effects and a limited efficacy on non-vertebral fracture reduction. Some sulfonylamidines targeting the scaffold proteins prohibitins-1 and 2 (PHB1/2) have been showed to inhibit the formation of osteoclasts in charge of bone resorption. Herein, we report the development of a second generation of anti-osteoclastic PHB ligands. The most potent compound, IN45, showed 88% inhibition at the low concentration of 5 μM, indicates that it might serve as a basis for the development of new antiosteoporotic drugs.
View MoreZhejiang Homart Chemical & Technology Co., Ltd.(expird)
Contact:13587107601
Address:Cuijiatianpu,Quzhou, Zhejiang, China (Mainland)
shanghai hekang chemical co.ltd
Contact:021-54173790
Address:328 WuHe Road, Building #A, 2nd Floor, Minhang, Shanghai 201109, China
Wuhan Sunrise Pharmaceutical Technology Co., Ltd
Contact:+86-27-83314682
Address:Room 340, New material Industrial base No.17, Gu Tian Five Lu , Qiaokou District, Wuhan , China
Changchun BC&HC Pharmaceutical Technology Co.,Ltd
Contact:+86-0431-80871588, +86-0431-80871788
Address:NO.668#Chuangxin road, Gaoxin District, Changchun ,Jilin
Fujian Xianyangyang Biotechnology Inc.
Contact:86-593-2805888
Address:No.23 Ningchuan North Road, Ningde, Fujian, China
Doi:10.1039/c5cc00430f
(2015)Doi:10.1021/jo971391b
(1997)Doi:10.1055/s-1997-986
(1997)Doi:10.1039/a705052f
(1997)Doi:10.1016/j.molliq.2021.115842
(2021)Doi:10.1016/j.bmc.2018.06.024
(2018)